• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

T细胞主要组织相容性复合体II类分子在LAG-3结合后下调CD4+ T细胞克隆反应。

T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding.

作者信息

Huard B, Prigent P, Pagès F, Bruniquel D, Triebel F

机构信息

Laboratoire d'Immunologie Cellulaire, INSERM U333, Institut Gustave-Roussy, Villejuif, France.

出版信息

Eur J Immunol. 1996 May;26(5):1180-6. doi: 10.1002/eji.1830260533.

DOI:10.1002/eji.1830260533
PMID:8647185
Abstract

T cell response to its antigen requires recognition by the T cell receptor together with a co-receptor molecule, either CD4 or CD8. Additional molecules have been identified that are capable of delivering the co-stimulatory signals provided by APC. Following T cell priming, a number of T cell activation antigens are expressed that may play a role in the inactivation phase of the T cell response. The lymphocyte activation gene (LAG)-3 protein and its counter-receptors, the major histocompatibility complex (MHC) class II molecules, are such activation antigens whose interaction may result in the down-regulation of the ongoing immune response. To investigate the role of LAG-3/class II molecule interaction, we produced a soluble form of LAG-3 by fusing the extracellular Ig domains of this membrane protein to the constant region of human IgG1 (LAG-3Ig). Here, we show a direct and specific binding of LAG-3Ig to class II molecules on the cell surface. In addition, we show that LAG-3/class II molecule interaction leads to the down-regulation of CD4+ Ag-specific T cell clone proliferation and cytokine secretion. This inhibitory effect is observed at the level of the effector cells and not the APC and is also found with anti-CD3 mAb, PHA + PMA or low-dose IL-2 driven stimulation in the absence of APC. These functional studies indicate that T cell MHC class II molecules down-regulate T cell proliferation following LAG-3 binding and suggest a role for LAG-3 in the control of the CD4+ T cell response.

摘要

T细胞对其抗原的应答需要T细胞受体与共受体分子(CD4或CD8)共同识别。已鉴定出其他一些能够传递由抗原呈递细胞(APC)提供的共刺激信号的分子。在T细胞致敏后,会表达多种T细胞活化抗原,它们可能在T细胞应答的失活阶段发挥作用。淋巴细胞活化基因(LAG)-3蛋白及其配体——主要组织相容性复合体(MHC)II类分子,就是这样的活化抗原,它们之间的相互作用可能导致正在进行的免疫应答下调。为了研究LAG-3/II类分子相互作用的作用,我们通过将这种膜蛋白的细胞外Ig结构域与人IgG1的恒定区融合,制备了一种可溶性形式的LAG-3(LAG-3Ig)。在此,我们展示了LAG-3Ig与细胞表面II类分子的直接特异性结合。此外,我们还表明,LAG-3/II类分子相互作用会导致CD4+抗原特异性T细胞克隆增殖和细胞因子分泌的下调。这种抑制作用在效应细胞水平上观察到,而不是在APC水平上,并且在没有APC的情况下,抗CD3单克隆抗体、PHA + PMA或低剂量IL-2驱动的刺激中也能发现。这些功能研究表明,T细胞MHC II类分子在LAG-3结合后下调T细胞增殖,并提示LAG-3在控制CD4+ T细胞应答中发挥作用。

相似文献

1
T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding.T细胞主要组织相容性复合体II类分子在LAG-3结合后下调CD4+ T细胞克隆反应。
Eur J Immunol. 1996 May;26(5):1180-6. doi: 10.1002/eji.1830260533.
2
CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins.用CD4和淋巴细胞激活基因-3(LAG-3)-Ig融合蛋白分析CD4/主要组织相容性复合体II类相互作用。
Eur J Immunol. 1995 Sep;25(9):2718-21. doi: 10.1002/eji.1830250949.
3
Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes.淋巴细胞激活基因3与主要组织相容性复合体II类分子的相互作用调节CD4+ T淋巴细胞的抗原反应。
Eur J Immunol. 1994 Dec;24(12):3216-21. doi: 10.1002/eji.1830241246.
4
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.浸润各种肿瘤类型的T淋巴细胞表达MHC II类配体淋巴细胞激活基因-3(LAG-3):LAG-3/MHC II类相互作用在细胞间接触中的作用。
Eur J Cancer. 2001 Sep;37(13):1709-18. doi: 10.1016/s0959-8049(01)00184-8.
5
Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).淋巴细胞激活基因-3(CD223)诱导树突状细胞的成熟与激活。
J Immunol. 2002 Apr 15;168(8):3874-80. doi: 10.4049/jimmunol.168.8.3874.
6
Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II.人类淋巴细胞激活基因-3(LAG-3)分子(一种MHC II类配体)的表达调控
Immunogenetics. 1998 Jul;48(2):116-24. doi: 10.1007/s002510050411.
7
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.MHC II类配体淋巴细胞激活基因-3在单克隆抗体或肽-MHC I类复合物与CD8和CD3-TCR分子结合后,与它们共同分布。
Int Immunol. 1999 Nov;11(11):1745-52. doi: 10.1093/intimm/11.11.1745.
8
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.LAG-3蛋白上主要组织相容性复合体II类结合位点的特征分析。
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9. doi: 10.1073/pnas.94.11.5744.
9
Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II.通过 LAG-3 介导的 MHC Ⅱ类分子跨胞吞作用间接抑制 CD4 T 细胞活化。
Cell Rep. 2024 Sep 24;43(9):114655. doi: 10.1016/j.celrep.2024.114655. Epub 2024 Aug 26.
10
Activation with superantigens induces programmed death in antigen-primed CD4+ class II+ major histocompatibility complex T lymphocytes via a CD11a/CD18-dependent mechanism.用超抗原激活可通过CD11a/CD18依赖性机制诱导抗原致敏的CD4+ II类主要组织相容性复合体T淋巴细胞发生程序性死亡。
Eur J Immunol. 1993 Jul;23(7):1513-22. doi: 10.1002/eji.1830230718.

引用本文的文献

1
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies.霍奇金淋巴瘤及其他血液系统恶性肿瘤中的免疫检查点分子
Cancers (Basel). 2025 Jul 10;17(14):2292. doi: 10.3390/cancers17142292.
2
Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing.通过靶向表观基因组编辑在CAR T细胞中实现持续且特异性的多重免疫检查点调节。
Mol Ther Nucleic Acids. 2025 Jul 1;36(3):102618. doi: 10.1016/j.omtn.2025.102618. eCollection 2025 Sep 9.
3
Molecular Insights into Cell-Mediated Immunity in Atypical Non-Ulcerated Cutaneous Leishmaniasis.
非典型非溃疡性皮肤利什曼病细胞介导免疫的分子见解
Microorganisms. 2025 Feb 13;13(2):413. doi: 10.3390/microorganisms13020413.
4
Advances in LAG3 cancer immunotherapeutics.LAG3癌症免疫疗法的进展
Trends Cancer. 2025 Jan;11(1):37-48. doi: 10.1016/j.trecan.2024.10.009. Epub 2024 Nov 26.
5
LAG-3-An incompletely understood target in cancer therapy.LAG-3——癌症治疗中一个尚未完全了解的靶点。
FASEB J. 2024 Nov 30;38(22):e70190. doi: 10.1096/fj.202401639R.
6
Checkpoint Inhibitors in Dogs: Are We There Yet?犬类中的免疫检查点抑制剂:我们做到了吗?
Cancers (Basel). 2024 May 24;16(11):2003. doi: 10.3390/cancers16112003.
7
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.可溶性免疫检查点:对癌症预后及免疫检查点治疗和常规治疗反应的影响。
J Exp Clin Cancer Res. 2024 May 31;43(1):155. doi: 10.1186/s13046-024-03074-z.
8
Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity.前沿:LAG3 二聚化是 TCR/CD3 相互作用和抑制抗肿瘤免疫所必需的。
J Immunol. 2024 Jul 1;213(1):7-13. doi: 10.4049/jimmunol.2300673.
9
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.免疫检查点抑制剂的作用机制:环状 RNA 调控与癌症标志相关的见解。
Cell Death Dis. 2024 Jan 4;15(1):3. doi: 10.1038/s41419-023-06389-5.
10
Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions.肺癌合并肺结核患者的免疫治疗与生物标志物:最新进展与未来方向
iScience. 2023 Sep 12;26(10):107881. doi: 10.1016/j.isci.2023.107881. eCollection 2023 Oct 20.